{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:16:02Z","timestamp":1793164562042,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02425-z","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:05:59Z","timestamp":1758809159000},"page":"2435-2440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Iptacopan\/LNP023 and rituximab as rescue therapy in a patient with\u00a0systemic lupus erythematosus-associated atypical haemolytic uraemic syndrome"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7504-5631","authenticated-orcid":false,"given":"Francesco","family":"Benvenuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Proglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Rigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sorbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"2","key":"2425_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N et al (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94(2):408\u2013418. https:\/\/doi.org\/10.1016\/j.kint.2018.02.029","journal-title":"Kidney Int"},{"issue":"4","key":"2425_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/cjn.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey MA, Ngo S et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8(4):554\u2013562. https:\/\/doi.org\/10.2215\/cjn.04760512","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2425_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","volume":"67","author":"CM Nester","year":"2015","unstructured":"Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH et al (2015) Atypical aHUS: state of the art. Mol Immunol 67(1):31\u201342. https:\/\/doi.org\/10.1016\/j.molimm.2015.03.246","journal-title":"Mol Immunol"},{"issue":"1","key":"2425_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/asheducation-2016.1.217","volume":"2016","author":"V Afshar-Kharghan","year":"2016","unstructured":"Afshar-Kharghan V (2016) Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016(1):217\u2013225. https:\/\/doi.org\/10.1182\/asheducation-2016.1.217","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2425_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9010003","author":"AI Pivovarova","year":"2020","unstructured":"Pivovarova AI, Thongprayoon C, Hansrivijit P, Kaewput W, Qureshi F, Boonpheng B et al (2020) Thrombotic microangiopathy among hospitalized patients with systemic lupus erythematosus in the United States. Dis Cases. https:\/\/doi.org\/10.3390\/diseases9010003","journal-title":"Dis Cases"},{"issue":"16","key":"2425_CR6","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM et al (2019) Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A 116(16):7926\u20137931. https:\/\/doi.org\/10.1073\/pnas.1820892116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"2425_CR7","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20203110S155c","volume":"36","author":"EKS Wong","year":"2021","unstructured":"Wong EKS, Praga M, Nester C (2021) Iptacopan (LNP023): a novel oral complement alternative pathway factor b inhibitor safely and effectively stabilises eGFR in C3 glomerulopathy. Nephrol Dial Transplant 36(Suppl 1):i25. https:\/\/doi.org\/10.1681\/ASN.20203110S155c","journal-title":"Nephrol Dial Transplant"},{"key":"2425_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00028-4","author":"AM Risitano","year":"2021","unstructured":"Risitano AM, R\u00f6th A, Soret J, Frieri C, de Fontbrune FS, Marano L et al (2021) Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. https:\/\/doi.org\/10.1016\/s2352-3026(21)00028-4","journal-title":"Lancet Haematol"},{"issue":"7","key":"2425_CR9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ekir.2023.04.029","volume":"8","author":"D Kavanagh","year":"2023","unstructured":"Kavanagh D, Greenbaum LA, Bagga A, Karki RG, Chen CW, Vasudevan S et al (2023) Design and rationale of the APPELHUS phase 3 open-label study of factor B inhibitor iptacopan for atypical hemolytic uremic syndrome. Kidney Int Rep 8(7):1332\u20131341. https:\/\/doi.org\/10.1016\/j.ekir.2023.04.029","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2425_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2425_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-020-01888-5","volume":"21","author":"RD Wright","year":"2020","unstructured":"Wright RD, Bannerman F, Beresford MW, Oni L (2020) A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 21(1):245. https:\/\/doi.org\/10.1186\/s12882-020-01888-5","journal-title":"BMC Nephrol"},{"key":"2425_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejim.2021.05.040","volume":"93","author":"N Martis","year":"2021","unstructured":"Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C et al (2021) Systemic autoimmune disorders associated with thrombotic microangiopathy: a cross-sectional analysis from the French national TMA registry: systemic autoimmune disease-associated TMA. Eur J Intern Med 93:78\u201386. https:\/\/doi.org\/10.1016\/j.ejim.2021.05.040","journal-title":"Eur J Intern Med"},{"issue":"9","key":"2425_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/blood.2022017860","volume":"141","author":"F Fakhouri","year":"2023","unstructured":"Fakhouri F, Schwotzer N, Fr\u00e9meaux-Bacchi V (2023) How i diagnose and treat atypical hemolytic uremic syndrome. Blood 141(9):984\u2013995. https:\/\/doi.org\/10.1182\/blood.2022017860","journal-title":"Blood"},{"issue":"16","key":"2425_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018833","volume":"142","author":"V Brocklebank","year":"2023","unstructured":"Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V et al (2023) Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood 142(16):1371\u20131386. https:\/\/doi.org\/10.1182\/blood.2022018833","journal-title":"Blood"},{"issue":"7","key":"2425_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/nejmoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL et al (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370(7):632\u2013639. https:\/\/doi.org\/10.1056\/nejmoa1311084","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02425-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:28Z","timestamp":1777564768000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/8\/2435\/8457505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2425"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02425-z","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco Benvenuti received consultant fees from Galapagos. Marta Proglio, Manuela Rigno and David Sorbo declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study (CLNP023B12002I) was approved by our ethics committee (Comitato etico territoriale area sud-ovest Veneto) on January, 17th, 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The patient provided consent to report the case.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}